 | • レポートコード：TPM-NV117 • 出版社/出版日：Transparency Market Research / 2019年8月22日 • レポート形態：英文、PDF、245ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、急性興奮及び攻撃治療の世界市場について調べ、急性興奮及び攻撃治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（第一世代抗精神病薬、第二世代抗精神病薬、ベンゾジアゼピン、その他）分析、投与経路別（経口、筋肉内、その他）分析、疾患別（統合失調症、認知症、双極性障害、うつ病、薬物誘発性激越および攻撃性、アルコール離脱、およびその他）分析、エンドユーザー別（病院および外来手術センター、精神科医療施設、その他）分析、関連企業情報などをまとめました。 ・急性興奮及び攻撃治療の市場概要 ・急性興奮及び攻撃治療の市場動向 ・急性興奮及び攻撃治療の世界市場規模・予測 ・急性興奮及び攻撃治療市場：薬物クラス別（第一世代抗精神病薬、第二世代抗精神病薬、ベンゾジアゼピン、その他） ・急性興奮及び攻撃治療市場：投与経路別（経口、筋肉内、その他） ・急性興奮及び攻撃治療市場：投与経路別（経口、筋肉内、その他） ・急性興奮及び攻撃治療市場：エンドユーザー別（病院および外来手術センター、精神科医療施設、その他） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Acute Agitation and Aggression Treatment Market – Scope of the Study
Transparency Market Research (TMR) conducted a comprehensive assessment regarding the growth potential of the acute agitation and aggression treatment market, in its latest research report, for the forecast period of 2019-2027. The research report consists of some distinguished insights for stakeholders for them to sustain their position and move to a higher market share. This exclusive research report is intended at providing rare and distinguished insights pertaining to the growth of the acute agitation and aggression treatment market, and offers information regarding the growth opportunities for market players. With the help of the insights mentioned in the research report, stakeholders in the acute agitation and aggression treatment market will be able to gain a brief outlook on its growth trajectory, which can help them in making well-informed strategies for their business growth.
The comprehensive business study analyzes and discusses Porter’s Five Forces, with a latent aim to provide the key growth strategies available in the acute agitation and aggression treatment market during the forecast period. This comprehensive guide provides key insights regarding the competition present in the acute agitation and aggression treatment market by identifying key competitors. This exclusive research report also offers information about the key strategies, financials, and notable developments of the acute agitation and aggression treatment market during the forecast period of 2019-2027. The acute agitation and aggression treatment market assessment has been conducted in terms of value (US$ Mn).
Acute Agitation and Aggression Treatment Market – Segmentation
In order to offer a microscopic as well as macroscopic view of the acute agitation and aggression treatment market, analysts and researchers of this research report have segregated the acute agitation and aggression treatment market on the basis of drug class, route of administration, end user, indication, and region. This exclusive business study also analyzes the incremental opportunity present in the acute agitation and aggression treatment market during the forecast period. Key segments of the acute agitation and aggression treatment market are as mentioned below:
Acute Agitation and Aggression Treatment Market – Key Questions Answered
This comprehensive research report analyzes and answers key questions concerning the growth of the acute agitation and aggression treatment market for the forecast period of 2019-2027. Some of the key questions answered in this research report are:
What are the recent developments and key market shifts expected to be witnessed in the acute agitation and aggression treatment market during the forecast period?
What are the key winning imperatives for leading and prominent players operating in the acute agitation and aggression treatment market?
What are the key trends propelling the growth of the acute agitation and aggression treatment market?
Which end user will exert a strong influence on the acute agitation and aggression treatment market?
Acute Agitation and Aggression Treatment Market – Research Methodology
The research undertaken by Transparency Market Research (TMR) analysts consists of a robust approach in order to cull key insights regarding the growth of the acute agitation and aggression market for the forecast period of 2019-2027. Interviews as well as discussions with leading opinion leaders, market heads, vendors, distributors, industry experts, and key players were carried out in order to conduct primary research. In addition to this, our analysts also conducted a thorough secondary study of marketing collaterals, industry associations, company websites, and government statistics.
レポート目次1 Preface
1.1 Market Definition and Scope
1.2 Market Segmentation
1.3 Key Research Objectives
1.4 Research Highlights
2 Assumptions and Acronyms
3 Research Methodology
4 Executive Summary
5 Market Overview
5.1 Product Overview
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increase in incidence of dementia in geriatric population
5.2.1.2 Rise in burden of mental illness and increase in agitation in patients
5.2.1.3 Economic burden of schizophrenia
5.2.1.4 Focus on creating awareness about agitation and aggression
5.2.1.5 Surge in prescriptions of anti-psychotics
5.2.2 Restraints
5.2.2.1 Social stigma associated with mental illness
5.2.2.2 Preference for non-pharmacological interventions
5.2.3 Opportunities
5.2.3.1 Ongoing research on the development of novel treatment for agitation
5.2.3.2 Agitation and Aggression – Unmet clinical needs
5.2.4 Global Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, 2017–2027
5.2.5 Global Acute Agitation and Aggression Treatment Market Outlook
5.2.6 Pipeline Analysis
5.2.7 Regulatory Scenario Assessment
5.2.8 Treatment Protocol
5.2.9 Key Strategies adopted by Market Players
5.2.10 Mental Health Spending
5.2.11 Healthcare Industry Overview
6 Global Acute Agitation and Aggression Treatment Market Analysis, by Drug Class
6.1 Introduction
6.2 Market Value Share Analysis, by Drug Class
6.3 Market Value Forecast, by Drug Class, 2017–2027
6.3.1 First-generation Anti-psychotics
6.3.2 Second-generation Anti-psychotics
6.3.3 Benzodiazepines
6.3.4 Others
6.4 Market Attractiveness, by Drug Class
7 Global Acute Agitation and Aggression Treatment Market Analysis, by Route of Administration
7.1 Introduction
7.2 Market Value Share Analysis, by Route of Administration
7.3 Market Value Forecast, by Route of Administration, 2017–2027
7.3.1 Oral
7.3.2 Intramuscular
7.3.3 Others
7.4 Market Attractiveness, by Route of Administration
8 Global Acute Agitation and Aggression Treatment Market Analysis, by Indication
8.1 Introduction
8.2 Market Value Share Analysis, by Indication
8.3 Market Value Forecast, by Indication, 2017–2027
8.3.1 Schizophrenia
8.3.2 Dementia
8.3.3 Bipolar Disorders
8.3.4 Depression
8.3.5 Alcohol Withdrawal
8.3.6 Drug-induced Agitation and Aggression
8.3.7 Others
8.4 Market Attractiveness, by Indication
9 Global Acute Agitation and Aggression Treatment Market Analysis, by End-user
9.1 Introduction
9.2 Market Value Share Analysis, by End-user
9.3 Market Value Forecast, by End-user, 2017–2027
9.3.1 Hospitals & Ambulatory Surgical Centers
9.3.1.1 Intensive Care Unit
9.3.1.2 Emergency Department
9.3.2 Psychiatric Care Facilities
9.3.3 Others
9.4 Market Attractiveness, by End-user
10 Global Acute Agitation and Aggression Treatment Market Analysis, by Region
10.1 Regional Outlook
10.2 Global Scenario
10.3 Introduction
10.4 Market Value Share Analysis, by Region
10.4.1 North America
10.4.2 Europe
10.4.3 Latin America
10.4.4 Asia Pacific
10.4.5 Middle East & Africa
10.5 Market Attractiveness Analysis, by Region
11 North America Acute Agitation and Aggression Treatment Market Analysis
11.1 Key Findings
11.2 Market Value Forecast, by Country, 2017–2027
11.2.1 U.S.
11.2.2 Canada
11.3 Market Value Forecast, by Drug Class, 2017–2027
11.3.1 First-generation Anti-psychotics
11.3.2 Second-generation Anti-psychotics
11.3.3 Benzodiazepines
11.3.4 Others
11.4 Market Value Forecast, by Route of Administration, 2017–2027
11.4.1 Oral
11.4.2 Intramuscular
11.4.3 Others
11.5 Market Value Forecast, by Indication, 2017–2027
11.5.1 Schizophrenia
11.5.2 Dementia
11.5.3 Bipolar Disorders
11.5.4 Depression
11.5.5 Alcohol Withdrawal
11.5.6 Drug-induced Agitation and Aggression
11.5.7 Others
11.6 Market Value Forecast, by End-user, 2017–2027
11.6.1 Hospitals & Ambulatory Surgical Centers
11.6.1.1 Intensive Care Unit
11.6.1.2 Emergency Department
11.6.2 Psychiatric Care Facilities
11.6.3 Others
11.7 Market Attractiveness Analysis
11.7.1 By Country
11.7.2 By Drug Class
11.7.3 By Route of Administration
11.7.4 By Indication
11.7.5 By End-user
12 Europe Acute Agitation and Aggression Treatment Market Analysis
12.1 Key Findings
12.2 Market Value Forecast, by Country/Sub-region, 2017–2027
12.2.1 U.K.
12.2.2 Germany
12.2.3 France
12.2.4 Italy
12.2.5 Spain
12.2.6 Rest of Europe
12.3 Market Value Forecast, by Drug Class, 2017–2027
12.3.1 First-generation Anti-psychotics
12.3.2 Second-generation Anti-psychotics
12.3.3 Benzodiazepines
12.3.4 Others
12.4 Market Value Forecast, by Route of Administration, 2017–2027
12.4.1 Oral
12.4.2 Intramuscular
12.4.3 Others
12.5 Market Value Forecast, by Indication, 2017–2027
12.5.1 Schizophrenia
12.5.2 Dementia
12.5.3 Bipolar Disorders
12.5.4 Depression
12.5.5 Alcohol Withdrawal
12.5.6 Drug-induced Agitation and Aggression
12.5.7 Others
12.6 Market Value Forecast, by End-user, 2017–2027
12.6.1 Hospitals & Ambulatory Surgical Centers
12.6.1.1 Intensive Care Unit
12.6.1.2 Emergency Department
12.6.2 Psychiatric Care Facilities
12.6.3 Others
12.7 Market Attractiveness Analysis
12.7.1 By Country/Sub-region
12.7.2 By Drug Class
12.7.3 By Route of Administration
12.7.4 By Indication
12.7.5 By End-user
13 Asia Pacific Acute Agitation and Aggression Treatment Market Analysis
13.1 Key Findings
13.2 Market Value Forecast, by Country/Sub-region, 2017–2027
13.2.1 China
13.2.2 Japan
13.2.3 India
13.2.4 Australia
13.2.5 Rest of Asia Pacific
13.3 Market Value Forecast, by Drug Class, 2017–2027
13.3.1 First-generation Anti-psychotics
13.3.2 Second-generation Anti-psychotics
13.3.3 Benzodiazepines
13.3.4 Others
13.4 Market Value Forecast, by Route of Administration, 2017–2027
13.4.1 Oral
13.4.2 Intramuscular
13.4.3 Others
13.5 Market Value Forecast, by Indication, 2017–2027
13.5.1 Schizophrenia
13.5.2 Dementia
13.5.3 Bipolar Disorders
13.5.4 Depression
13.5.5 Alcohol Withdrawal
13.5.6 Drug-induced Agitation and Aggression
13.5.7 Others
13.6 Market Value Forecast, by End-user, 2017–2027
13.6.1 Hospitals & Ambulatory Surgical Centers
13.6.1.1 Intensive Care Unit
13.6.1.2 Emergency Department
13.6.2 Psychiatric Care Facilities
13.6.3 Others
13.7 Market Attractiveness Analysis
13.7.1 By Country/Sub-region
13.7.2 By Drug Class
13.7.3 By Route of Administration
13.7.4 By Indication
13.7.5 By End-user
14 Latin America Acute Agitation and Aggression Treatment Market Analysis
14.1 Key Findings
14.2 Market Value Forecast, by Country/Sub-region, 2017–2027
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America
14.3 Market Value Forecast, by Drug Class, 2017–2027
14.3.1 First-generation Anti-psychotics
14.3.2 Second-generation Anti-psychotics
14.3.3 Benzodiazepines
14.3.4 Others
14.4 Market Value Forecast, by Route of Administration, 2017–2027
14.4.1 Oral
14.4.2 Intramuscular
14.4.3 Others
14.5 Market Value Forecast, by Indication, 2017–2027
14.5.1 Schizophrenia
14.5.2 Dementia
14.5.3 Bipolar Disorders
14.5.4 Depression
14.5.5 Alcohol Withdrawal
14.5.6 Drug-induced Agitation and Aggression
14.5.7 Others
14.6 Market Value Forecast, by End-user, 2017–2027
14.6.1 Hospitals & Ambulatory Surgical Centers
14.6.1.1 Intensive Care Unit
14.6.1.2 Emergency Department
14.6.2 Psychiatric Care Facilities
14.6.3 Others
14.7 Market Attractiveness Analysis
14.7.1 By Country/Sub-region
14.7.2 By Drug Class
14.7.3 By Route of Administration
14.7.4 By Indication
14.7.5 By End-user
15 Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis
15.1 Key Findings
15.2 Market Value Forecast, by Country/Sub-region, 2017–2027
15.2.1 GCC Countries
15.2.2 Israel
15.2.3 South Africa
15.2.4 Rest of Middle East & Africa
15.3 Market Value Forecast, by Drug Class, 2017–2027
15.3.1 First-generation Anti-psychotics
15.3.2 Second-generation Anti-psychotics
15.3.3 Benzodiazepines
15.3.4 Others
15.4 Market Value Forecast, by Route of Administration, 2017–2027
15.4.1 Oral
15.4.2 Intramuscular
15.4.3 Others
15.5 Market Value Forecast, by Indication, 2017–2027
15.5.1 Schizophrenia
15.5.2 Dementia
15.5.3 Bipolar Disorders
15.5.4 Depression
15.5.5 Alcohol Withdrawal
15.5.6 Drug-induced Agitation and Aggression
15.5.7 Others
15.6 Market Value Forecast, by End-user, 2017–2027
15.6.1 Hospitals & Ambulatory Surgical Centers
15.6.1.1 Intensive Care Unit
15.6.1.2 Emergency Department
15.6.2 Psychiatric Care Facilities
15.6.3 Others
15.7 Market Attractiveness Analysis
15.7.1 By Country/Sub-region
15.7.2 By Drug Class
15.7.3 By Route of Administration
15.7.4 By Indication
15.7.5 By End-user
16 Company Profiles
16.1 Eli Lilly and Company
16.1.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.1.2 Financial Overview
16.1.3 SWOT Analysis
16.1.4 Strategic Overview
16.2 Pfizer, Inc.
16.2.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.2.2 Financial Overview
16.2.3 SWOT Analysis
16.2.4 Strategic Overview
16.3 Ono Pharmaceutical Co., Ltd.
16.3.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.3.2 Financial Overview
16.3.3 SWOT Analysis
16.3.4 Strategic Overview
16.4 Otsuka Holdings Co., Ltd.
16.4.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.2 Financial Overview
16.4.3 SWOT Analysis
16.4.4 Strategic Overview
16.5 GlaxoSmithKline plc
16.5.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.5.2 Financial Overview
16.5.3 SWOT Analysis
16.5.4 Strategic Overview
16.6 Bristol-Myers Squibb Company
16.6.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.6.2 Financial Overview
16.6.3 SWOT Analysis
16.6.4 Strategic Overview
16.7 Janssen Biotech, Inc. (Johnson & Johnson)
16.7.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.7.2 Financial Overview
16.7.3 SWOT Analysis
16.7.4 Strategic Overview
16.8 H. Lundbeck A/S
16.8.1 Company Overview (Headquarters, Business Segments, Employee Strength)
16.8.2 Financial Overview
16.8.3 SWOT Analysis
16.8.4 Strategic Overview
Table 01: Pipeline Analysis – Acute Agitation and Aggression Treatment
Table 02: Principle difference between U.S., EU and India
Table 03: Regulatory Scenario Assessment - Administrative Requirements
Table 04: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 06: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2016–2026
Table 07: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027
Table 09: Global Acute Agitation and Aggression Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2027
Table 10: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 11: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 12: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Intramuscular Benzodiazepines, 2017–2027
Table 13: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027
Table 17: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 19: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027
Table 23: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 24: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 25: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027
Table 29: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 30: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 31: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 32: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027
Table 35: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 37: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 38: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 39: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 40: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Hospitals & Ambulatory Surgical Centers, 2017–2027